Drug Trial Radar · NCT05422612
Department of Defense PTSD Adaptive Platform Trial - Master Protocol
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Suspended
Enrollment
800
Planned (sponsor's estimate)
Start
Nov 2, 2023
Primary completion
Jul 2028
Study completion Jul 2029
Sponsor
- Lead sponsor
- Global Coalition for Adaptive ResearchAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- U.S. Army Medical Research and Development Command; PPD Development, LP; Berry Consultants; Idorsia Pharmaceuticals Ltd.; Cambridge Cognition Ltd; Citeline
- First posted
- Jun 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design. Participants are randomized among the available cohorts in the study and the resulting randomization enables sharing/pooling of control participants, where all interventions may be compared to a common control (placebo). The master protocol describes the default procedures and analyses for all cohorts; treatment-specific eligibility requirements, safety and efficacy procedures, or endpoints are described in the cohort-specific appendices and reflected in the intervention-specific clinicaltrials.gov records.
Conditions
- Post Traumatic Stress Disorder
Interventions
Intervention A Fluoxetine Hydrochloride (HCl)Drug
Fluoxetine will be administered at 10 to 60 mg daily. The initial dose for all participants will be 10 mg daily for 1 week, then increased to 20 mg daily for 2 weeks, then increased to 40 mg daily for 2 weeks, then increased to 60 mg daily for the remainder of the trial. One reduction in dose due to tolerability will be allowed. When a participant's dose is decreased due to tolerability, the dose will not be increased.
Intervention A PlaceboDrug
A matching placebo will be administered at 10 to 60 mg daily in the same regimen as the intervention.
Intervention B Vilazodone Hydrochloride (HCl)Drug
Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.
Intervention B PlaceboDrug
A matching placebo will be administered at 10 to 40 mg daily in the same regimen as the intervention.
Intervention C DaridorexantDrug
Daridorexant will be administered 50 mg once daily.
Intervention C PlaceboDrug
A matching placebo will be administered at 50 mg daily in the same regimen as the intervention.
Intervention D SLS-002Drug
• SLS-002 will be administered via intranasal administration (one spray per nostril, per device) at 78 mg two times per week for the first eight weeks and then once a week for the last four weeks.
Intervention D PlaceboDrug
A matching placebo will be administered via intranasal administration (one spray per nostril, per device) two times per week for the first eight weeks and then once a week for the last four weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change in the Clinician-Administered PTSD Scale-5-Revised (CAPS-5-R) Past Month total score at Week 12 (Final/Early termination Visit).Time frame: 12 Weeks
- Incidence of new or worsening suicidal thoughts or behaviors as measured by change in Columbia Suicide Severity Rating Scale (C-SSRS) score from baseline.Time frame: 12 Weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Homestead Associates in Research, Inc.
Miami, Florida
Advanced Discovery Research
Atlanta, Georgia
Tripler Army Medical Center (TAMC)
Tripler AMC, Hawaii
Cincinnati Veteran's Affairs Medical Center
Fort Thomas, Kentucky
Walter Reed National Military Medical Center (WRNMC)
Bethesda, Maryland
Upstate Clinical Research Associates, LLC
Williamsville, New York
Wilford Hall Ambulatory Surgical Center (WHASC)
San Antonio, Texas
Alexander T. Augusta Military Medical Center (ATAMMC):
Fort Belvoir, Virginia
Madigan Army Medical Center
Joint Base Lewis McChord, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.